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OBJECTIVE — The accurate quantiﬁcation of human diabetic neuropathy is important to
deﬁne at-risk patients, anticipate deterioration, and assess new therapies.
RESEARCH DESIGN AND METHODS — A total of 101 diabetic patients and 17
age-matched control subjects underwent neurological evaluation, neurophysiology tests, quan-
titativesensorytesting,andevaluationofcornealsensationandcornealnervemorphologyusing
corneal confocal microscopy (CCM).
RESULTS — Corneal sensation decreased signiﬁcantly (P  0.0001) with increasing neuro-
pathic severity and correlated with the neuropathy disability score (NDS) (r  0.441, P 
0.0001). Corneal nerve ﬁber density (NFD) (P  0.0001), nerve ﬁber length (NFL), (P 
0.0001), and nerve branch density (NBD) (P  0.0001) decreased signiﬁcantly with increasing
neuropathicseverityandcorrelatedwithNDS(NFDr0.475,P0.0001;NBDr0.511,
P  0.0001; and NFL r  0.581, P  0.0001). NBD and NFL demonstrated a signiﬁcant and
progressive reduction with worsening heat pain thresholds (P  0.01). Receiver operating
characteristic curve analysis for the diagnosis of neuropathy (NDS 3) deﬁned an NFD of
27.8/mm
2 with a sensitivity of 0.82 (95% CI 0.68–0.92) and speciﬁcity of 0.52 (0.40–0.64)
and for detecting patients at risk of foot ulceration (NDS 6) deﬁned a NFD cutoff of 20.8/
mm
2 with a sensitivity of 0.71 (0.42–0.92) and speciﬁcity of 0.64 (0.54–0.74).
CONCLUSIONS — CCMisanoninvasiveclinicaltechniquethatmaybeusedtodetectearly
nerve damage and stratify diabetic patients with increasing neuropathic severity.
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E
stablished diabetic neuropathy leads
to pain and foot ulceration. Detect-
ing neuropathy early may allow in-
tervention with treatments to slow or
reverse this condition (1). Recent studies
suggested that small unmyelinated C-
ﬁbers are damaged early in diabetic neu-
ropathy (2–4) but can only be detected
using invasive procedures such as sural
nerve biopsy (4,5) or skin-punch biopsy
(6–8). Our studies have shown that cor-
neal confocal microscopy (CCM) can
identify early small nerve ﬁber damage
and accurately quantify the severity of di-
abetic neuropathy (9–11). We have also
shownthatCCMrelatestointraepidermal
nerve ﬁber loss (12) and a reduction in
corneal sensitivity (13) and detects early
nerve ﬁber regeneration after pancreas
transplantation (14). Recently we have
also shown that CCM detects nerve ﬁber
damage in patients with Fabry disease
(15) and idiopathic small ﬁber neuropa-
thy (16) when results of electrophysiol-
ogy tests and quantitative sensory testing
(QST) are normal.
In this study we assessed corneal sen-
sitivityandcornealnervemorphologyus-
ing CCM in diabetic patients stratiﬁed for
the severity of diabetic neuropathy using
neurological evaluation, electrophysiol-
ogy tests, and QST. This enabled us to
compare CCM and corneal esthesiometry
with established tests of diabetic neurop-
athy and deﬁne their sensitivity and spec-
iﬁcity to detect diabetic patients with
early neuropathy and those at risk of foot
ulceration.
RESEARCH DESIGN AND
METHODS— A total of 101 diabetic
patients and 17 nondiabetic healthy vol-
unteers participated in the study. Patients
were excluded if they had another cause
of neuropathy, had absent pedal pulses,
wore contact lenses, or had a history of
corneal trauma or surgery. The protocol
was approved by the local research ethics
committee of the Greater Manchester
Health Authority, and all subjects gave
written informed consent.
Evaluation of neuropathic severity
The neuropathy deﬁcit score (NDS) was
established by neurological examination
and the severity of neuropathy was deter-
mined: NDS 0–2, no neuropathy; NDS
3–5, mild neuropathy; NDS, 6–8, mod-
erate neuropathy; and NDS, 9–10, severe
neuropathy (17,18). QST included as-
sessment of vibration perception thresh-
old (VPT), using a neurothesiometer
(Horwell Scientiﬁc Laboratory Supplies,
Wilford, Nottingham, U.K.); heat as pain
thresholds (C-ﬁbers); and cooling detec-
tion thresholds (A- ﬁbers) using a CASE
IV system (WR Medical Electronics, Still-
water,MN)withthethresholdsforabnor-
mality set at the 95th percentile. The
DANTEC Keypoint electromyography
system (software version 1.4) was used to
quantify sural sensory and peroneal mo-
tor nerve conduction velocity and ampli-
tude in all subjects.
Corneal sensitivity
Corneal sensitivity was assessed using a
noncontact corneal aesthesiometer
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center of the cornea, lasting 0.9 s and ex-
erting a force expressed in millibars (13).
The coefﬁcient of variation for NCCA is
5.6%.
CCM
One eye of each subject was selected at
random and examined with a Tomey
ConfoScanmodelP4usingpreviouslyde-
scribed methodology (10,12). Three to
ﬁve high-quality images of the sub-basal
nerveplexusfromthecenterofthecornea
were assessed from each diabetic patient
and control subject in a randomized
masked fashion.
Three parameters were quantiﬁed
(9,10,12): corneal nerve ﬁber density
(NFD), the total number of major nerves
per square millimeter; nerve ﬁber length
(NFL), the total length of all nerve ﬁbers
andbranches(millimeterspersquaremil-
limeter); and nerve branch density
(NBD), the number of branches emanat-
ing from major nerve trunks per square
millimeter.
Statistical methods
SPSS (version 11.05.0) was used to com-
pute the results. Data are presented as
means  SEM. The data were not nor-
mally distributed; hence, ANOVA with
Scheffe ´ post hoc tests were used to estab-
lish differences among the ﬁve (control,
none,mild,moderate,andseverediabetic
neuropathy) groups. The Pearson coefﬁ-
cient test was used to analyze correlations
between variables. Receiver operating
characteristic (ROC) curve analysis estab-
lished the area under the curve (AUC) to
determine the optimal threshold, sensi-
tivity, and speciﬁcity values to estimate
precisionforNFD,NBD,NFL,andNCCA
in deﬁning the presence of neuropathy
(NDS 3) and risk of foot ulceration
(NDS 6). The ROC curves were used to
compare the four tests and to deﬁne the
optimum cutoff points, whereby sensitiv-
ity and speciﬁcity were equally weighted.
RESULTS— Atotalof101diabeticpa-
tients aged 58  2.0 years and 17 age-
matched(554.8years)controlsubjects
were studied (Table 1). Diabetic patients
were stratiﬁed according to NDS: none
(1.4  0.1, n  34), mild (3.8  0.1, n 
37), moderate (6.5  0.1, n  16), and
severe (9.7  0.1, n  14). Age, duration
ofdiabetes,andA1Cdidnotdifferamong
groups. and there was no correlation be-
tween NDS and A1C (r  0.098, P 
0.36).
Peroneal and sural nerve conduction
velocities did not differ in patients with-
out neuropathy but were signiﬁcantly re-
duced in those with mild (P  0.001 and
P  0.05), moderate (P  0.001 and P 
0.01), and severe (P  0.001 and P 
0.001) neuropathy. Likewise, sural nerve
amplitude did not differ in diabetic pa-
tients without neuropathy but was signif-
icantly reduced in those with mild,
moderate, and severe (P  0.001) neu-
ropathy. Peroneal nerve amplitude was
signiﬁcantly reduced in diabetic patients
without (P  0.05) and with mild, mod-
erate,andsevere(P0.001)neuropathy.
VPT increased signiﬁcantly with se-
verityofneuropathy(P0.0001)butdid
not differ in patients without neuropathy
(P  1.0) and was only signiﬁcant in
those with mild (P  0.01), moderate
(P  0.0001), and severe (P  0.0001)
neuropathy. Cold detection threshold
was signiﬁcantly increased in those with
mild (P  0.01), moderate (P  0.0001),
and severe (P  0.0001) neuropathy.
Heat pain perception thresholds in-
creased signiﬁcantly with increasing neu-
ropathic severity (P  0.05).
Corneal sensitivity decreased in dia-
betic patients compared with that in con-
trol subjects (P  0.0001). However, this
was signiﬁcant only in patients with se-
vere neuropathy (P  0.001) (Table 1).
Qualitatively there was a reduction in
nerve ﬁber and branch density in diabetic
patients compared with that in control
subjects (Fig. 1). Intraindividual variabil-
ity was established by repeating CCM in
15 subjects on two occasions, and the co-
efﬁcient of variation was 12% for NFD,
9% for NFL, and 24% for NBD. Corneal
Table1—Clinicaldemographics,clinicalneuropathyevaluation,QST,electrophysiologytests,andcornealsensitivitywithNCCAandCCMof
the nerve ﬁbers in Bowman layer of the cornea in control subjects and diabetic patients with increasing neuropathic severity
Parameter Control
Neuropathy
No Mild Moderate Severe
n 17 34 37 16 14
Age (years) 55  4.8 55  1.9 58  2.1 59  2.5 61  2.05
Diabetes duration (years) 0 10.7  1.82 15.5  2.08 18.6  3.06 19.3  2.85
Diabetes type (1/2) — 2/32 9/28 4/12 2/12
Sex (male/female) 8/9 19/15 32/5 12/4 10/4
A1C (%) 6.5 8.1  0.27 7.9  0.23 8.4  0.37 8.3  0.38
NDS* 0 1.4  0.15¶ 3.8  0.11¶ 6.5  0.18¶ 9.7  0.11¶
SNCV (40) (m/s)* 47.85  2.62 42.88  0.92 41.10  0.83† 36.78  1.88‡ 37.26  2.60†
Sural amplitude (A) (5)* 18.62  2.55 13.74  1.46 6.13  0.73¶ 4.05  0.67¶ 6.16  3.25†
PMNCV (40) (m/s)* 49.26  1.63 44.60  0.65 41.21  0.72¶ 35.77  1.68¶ 33.82  2.60¶
Peroneal amplitude (2)* 5.58  1.02 3.58  0.28† 2.10  0.25¶ 1.62  0.28¶ 1.16  0.50¶
VPT (V)* 9.58  0.93 9.56  0.84 18.18  1.96† 25.35  2.85¶ 42.29  3.83¶
CDT (percentile) — 54.64  3.89 76.08  4.1‡ 89.60  4.9¶ 98.40  0.89¶
NCCA (mbar)* 0.72  0.36 1.16  0.07 1.34  0.10 1.49  0.20 2.23  0.51¶
NFD (no./mm
2)* 45.60  4.47 31.63  2.33† 28.36  1.95¶ 18.57  3.63¶ 17.84  2.49¶
NBD (no./mm
2)* 25.38  2.99 17.42  2.02† 13.28  1.79¶ 5.63  1.33¶ 4.95  1.79¶
NFL (mm/mm
2)* 11.21  0.88 8.05  0.71 5.48  0.45¶ 3.01  0.39¶ 2.99  0.34¶
Data are means  SEM for diabetic patients and control subjects. CDT, cold detection threshold; PMNCV, peroneal motor nerve conduction velocity; SNCV, sural
nerve conduction velocity. *Statistically signiﬁcant difference between diabetic patients and controls using ANOVA: P  0.001. Post hoc results with signiﬁcant
difference between control subjects and diabetic patients with differing severity of neuropathy: †P  0.05; ‡P  0.01, ¶P  0.001.
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branch density (P  0.0001). and
length (P  0.0001) were signiﬁcantly
and progressively reduced in diabetic
patients (Table 1, Fig. 2). NFD was sig-
niﬁcantly reduced in diabetic patients
with no (P  0.02), mild (P  0.001),
moderate(P  0.0001),andsevere(P 
0.0001) neuropathy compared with
that in control subjects (Fig. 2A). Simi-
larly, NBD was signiﬁcantly reduced in
diabetic patients with no (P  0.03),
mild (P  0.001), moderate (P 
0.0001), and severe (P  0.0001) neu-
ropathy compared with that in control
subjects (Fig. 2B). NFL was reduced in
diabetic patients with no (P  0.07),
mild (P  0.0001), moderate (P 
0.0001), and severe (P  0.0001) neu-
ropathy compared with that in control
subjects (Fig. 2C). NDS correlated sig-
niﬁcantly with corneal sensitivity (r 
0.44, P  0.0001), NFD (r  0.44,
P  0.0001), NBD (r  0.44, P 
0.0001), and NFL (r  0.57, P 
0.0001).
According to the heat pain thresh-
old (HPT), patients were classiﬁed into
four groups: normal (percentile 0–25);
mild (percentile 26–50); moderate
(percentile 51–75), and severe (percen-
tile 76–100) neuropathy (Table 2).
NCCA increased and NFD decreased
with increasing HPTs but were not sig-
niﬁcant. However, NBD and NFL dem-
onstrated a progressive reduction with
worsening HPT (P  0.01).
CCM sensitivity and speciﬁcity
(Table 3)
AccordingtotheROCcurves(Fig.3)for
the three CCM parameters for NDS 3,
AUC was 0.76 for NFD, 0.79 for NBD,
and 0.84 for NFL and for NDS 6 AUC
was 0.76 for NFD, 0.79 for NBD, and
0.81 for NFL. Because the ROC curve
(Fig.3A)forNFLwasgreaterthanthose
for the other two variables, it is consid-
ered to be the better test for diagnosing
diabetic neuropathy, although for high
values of speciﬁcity NFD and NBD may
be considered better tests. For those at
risk of foot ulceration, the ROC curves
for the three CCM parameters (Fig. 3B)
aremorecomparable,althoughNFLhas
a higher speciﬁcity than the other tests.
For the diagnosis of neuropathy, the
sensitivity and speciﬁcity were, respec-
tively, 82 and 52% for NFD, 91 and
45% for NBD, 64 and 79% for NFL, and
60 and 61% for NCAA. For detecting
those at risk of foot ulceration the sen-
sitivity and speciﬁcity were 71 and 64%
Figure1—ImagesofcornealnervesinBowmanlayer,showingabundantnerveﬁbersandadequatebranchinginacontrolsubject(A)withatypical
image from a diabetic patient with mild (B), moderate (C), and severe (D) neuropathy showing a progressive loss of nerve ﬁbers.
CCM: noninvasive test for diabetic neuropathy
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71% for NFL, and 23 and 89% for
NCCA.
CONCLUSIONS — It is important to
detectnervedamageattheearlieststageof
diabetic neuropathy as intervention at
thisstagewithimprovedglycemiccontrol
(Diabetes Control and Complications
Trial) (19) or improvement of other risk
factors (20,21) may prevent nerve degen-
eration or promote regeneration. Al-
though diabetic patients with established
neuropathy have increased vibration and
thermal perception and decreased nerve
conduction velocity, and early detection
of neuropathy is difﬁcult (22). Recent
studies show signiﬁcant intraepidermal
nerve ﬁber (IENF) loss in skin biopsies,
despite normal results for electrophysiol-
ogy tests and QST (2,3), suggesting that
IENF assessment may be important in the
early diagnosis of neuropathy (23). How-
ever, because skin biopsy is an invasive
procedure, in this study we assessed the
utility of two novel noninvasive measures
of neuropathy, namely corneal esthesi-
ometry and corneal confocal microscopy.
An early study of type 1 diabetic pa-
tients demonstrated a reduction in cor-
nealsensitivityandthenumberofcorneal
nerve ﬁber bundles, which correlated sig-
niﬁcantly with the severity of neuropathy
(24). We have previously demonstrated a
signiﬁcantreductionincornealsensitivity
using two independent measures and
Figure 2—Corneal nerve morphology in control subjects and diabetic patients with increasing neuropathic severity:A: NFD (P  0.0001); B: NBD
(P  0.0001); C: NFL (P  0.0001).
Table 2—Results of corneal nerve parameters in diabetic patients stratiﬁed for severity of
neuropathy according to the HPT
Neuropathy
P value No Mild Moderate Severe
n 34 37 16 15
NFD (no./mm
2) 28.63  2.51 25.73  2.27 22.00  4.99 23.26  3.26 0.44
NBD (no./mm
2) 15.13  2.09 13.79  2.13 8.60  2.20 5.65  1.37 0.01
NFL (mm/mm
2) 6.54  0.65 5.75  0.74 4.90  1.18 3.27  0.24 0.01
NCCA (mbar) 1.19  0.07 1.38  0.11 1.83  0.43 1.75  0.38 0.11
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(13).Ourstudies(9,10)usingCCMdem-
onstrated corneal nerve ﬁber abnormali-
ties, which were related to the severity of
somatic neuropathy. More recently, we
have shown that CCM reﬂects IENF loss
in skin biopsies from the dorsum of the
footindiabeticpatients(12)andmayalso
show nerve repair after pancreas trans-
plantation (14). Furthermore, we have
recently demonstrated that CCM de-
tectssmallﬁberdamageinpatientswith
Fabry disease (15) and idiopathic small
ﬁber neuropathy (16), indicating that
CCM is a direct surrogate of peripheral
neuropathy.
We now demonstrate a progressive
reduction in corneal sensitivity and in-
creasing corneal nerve degeneration with
increasing severity of diabetic neuropa-
thy. Importantly, corneal nerve ﬁber
damagewaspresentinpatientsdeemedto
have no evidence of neuropathy based on
neurological evaluation, QST, and neuro-
physiology tests, consistent with the re-
centstudiesshowingIENFlossindiabetic
patients without neuropathy (2,3). We
alsoestablishfortheﬁrsttimethatcorneal
esthesiometry and CCM have reasonable
sensitivity and speciﬁcity to detect dia-
betic patients with minimal neuropathy
and those at risk of foot ulceration. A lim-
itation of this study is that the data are
derived from a cross-sectional study. Ide-
ally a longitudinal study would provide
more robust data regarding the ability of
CCM to identify patients at risk of devel-
oping neuropathy.
Ideally, a test for detecting neuropa-
thy in the early stages should be noninva-
sive and quantitative and detect changes
with time or in response to therapeutic
interventions (2). CCM seems to fulﬁll
these attributes, especially because it is
noninvasive, directly quantiﬁes small ﬁ-
ber pathology, and stratiﬁes neuropathic
severity. CCM may therefore be an ideal
surrogate marker for early diagnosis,
Figure 3—ROC curves for NFD, NBD, and NFL for (A) NDS 3 and (B) NDS 6. Diagonal
segments are produced by ties.
Table 3—Diagnostic efﬁciency of corneal nerve parameters presented as AUC and P values with CCM and NCCA cutoffs with sensitivity and
speciﬁcity for diagnosis of patients with neuropathy (NDS >3) and for diagnosis of patients at risk of foot ulceration (NDS >6)
Variable
NDS 3 NDS 6
AUC P value
Optimum
cutoff Sensitivity Speciﬁcity AUC P value
Optimum
cutoff Sensitivity Speciﬁcity
NFD 0.764 0.0001 27.81 0.82 (0.68–0.92) 0.52 (0.40–0.64) 0.751 0.0001 20.82 0.71 (0.42–0.92) 0.64 (0.54–0.74)
NBD 0.801 0.0001 13.89 0.91 (0.79–0.98) 0.45 (0.34–0.57) 0.783 0.0001 6.94 0.71 (0.42–0.92) 0.71 (0.61–0.80)
NFL 0.849 0.0001 3.39 0.64 (0.49–0.78) 0.79 (0.68–0.88) 0.813 0.0001 3.29 0.64 (0.35–0.87) 0.71 (0.61–0.80)
NCCA 0.678 0.001 1.12 0.60 (0.44–0.75) 0.61 (0.48–0.72) 0.720 0.003 2.1 0.23 (0.05–0.54) 0.89 (0.80–0.94)
Data in parentheses are 95% CI.
CCM: noninvasive test for diabetic neuropathy
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of therapeutic efﬁcacy of new treatments
in human diabetic neuropathy.
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